Richter Transformation in the Era of Targeted Therapies

Neoadjuvant T-DXd produced faster imaging responses vs ddAC in DESTINY-Breast11, but imaging poorly predicted pCR.

Abemaciclib plus fulvestrant showed a numerical yet nonsignificant overall survival trend after CDK4/6 inhibitor progression in final postMONARCH data.

INCB123667 with bevacizumab showed antitumor activity in heavily pretreated, cyclin E1–overexpressing platinum-resistant ovarian cancer.

Selective CDK4 inhibitor atirmociclib plus fulvestrant reduced risk of progression or death by 40% vs investigator's choice of therapy in the phase 2 FOURLIGHT-1 trial.

Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.

The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.

The claudin 6–targeted antibody-drug conjugate ixotatug vedotin showed antitumor activity in recurrent germ cell tumors, including after transplant.

An exploratory analysis of the phase 3 KEYNOTE-B15 trial found that ctDNA status was strongly prognostic for event-free survival regardless of treatment arm.